NATURE’S SUNSHINE PRODUCTS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.09M, a 8.61% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.01M, a 31.85% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.16M, a 12.19% increase year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.12M, a 2.67% increase year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $4.95M, a 8.63% decline from fiscal 2024.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $5.42M, a 22.71% increase from fiscal 2023.
- NATURE’S SUNSHINE PRODUCTS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $4.42M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.10M 10-Q · filed 2026-08-06 | $3.26M derived: sum of 3 quarters · filed 2026-08-06 | $4.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-07 | $2.17M derived: sum of 2 quarters · filed 2026-05-07 | $3.29M derived: sum of 3 quarters · filed 2026-05-07 | $4.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.28M derived: sum of 2 quarters · filed 2026-03-10 | $3.47M derived: sum of 3 quarters · filed 2026-08-06 | $4.95M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.31M derived: sum of 2 quarters · filed 2026-08-06 | $3.79M 10-Q · filed 2025-11-06 | $4.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.67M 10-Q · filed 2026-08-06 | $3.71M derived: sum of 3 quarters · filed 2026-08-06 | $4.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-07 | $2.51M derived: sum of 2 quarters · filed 2026-05-07 | $3.60M derived: sum of 3 quarters · filed 2026-05-07 | $5.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.12M derived: sum of 2 quarters · filed 2026-03-10 | $4.22M derived: sum of 3 quarters · filed 2026-03-10 | $5.42M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.19M derived: sum of 2 quarters · filed 2025-11-06 | $4.39M 10-Q · filed 2025-11-06 | $5.51M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.30M 10-Q · filed 2025-07-31 | $4.42M derived: sum of 3 quarters · filed 2025-07-31 | $5.61M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-06 | $2.32M derived: sum of 2 quarters · filed 2025-05-06 | $3.51M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.31M derived: sum of 2 quarters · filed 2025-03-11 | $4.42M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.29M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $2.10M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |